Pure Global

Effect of Continuing Versus Holding Metformin During Hospitalizations. - Trial NCT06296836

Access comprehensive clinical trial information for NCT06296836 through Pure Global AI's free database. This Phase 4 trial is sponsored by University of Illinois at Chicago and is currently Not yet recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06296836
Phase 4
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06296836
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Effect of Continuing Versus Holding Metformin During Hospitalizations.
Effect of Continuing Versus Holding Metformin During Hospitalizations to Internal Medicine on Glucose Control, Acidosis, Abdominal Symptoms, Length of Stay, and Mortality.

Study Focus

Diabetes Mellitus, Type 2

Metformin

Interventional

drug

Sponsor & Location

University of Illinois at Chicago

Chicago, United States of America

Timeline & Enrollment

Phase 4

Apr 01, 2024

Jun 30, 2026

300 participants

Primary Outcome

Mean glucose levels

Summary

A randomized study of continuing versus holding metformin during hospitalizations to internal
 medicine services to determine the effects on glucose control, acidosis, abdominal symptoms,
 length of stay, and mortality.

ICD-10 Classifications

Type 2 diabetes mellitus
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications

Data Source

ClinicalTrials.gov

NCT06296836

Non-Device Trial